PB1902: ASC4OPT TRIAL IN PROGRESS: A PHASE 3B OPEN-LABEL OPTIMIZATION STUDY OF ORAL ASCIMINIB IN CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE PREVIOUSLY TREATED WITH 2 OR MORE TYROSINE KINASE INHIBITORS

PB1902: ASC4OPT TRIAL IN PROGRESS: A PHASE 3B OPEN-LABEL OPTIMIZATION STUDY OF ORAL ASCIMINIB IN CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE PREVIOUSLY TREATED WITH 2 OR MORE TYROSINE KINASE INHIBITORS

Bibliographic Details
Main Authors:	M. Breccia, A. Turkina, C. Boquimpani, C. Chuah, G. Sharf, P. Schuld, M. Hoch, J. Yssel, Y. Zhang, A. Hochhaus
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000850460.97022.94

Similar Items

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
by: Andreas Hochhaus, et al.
Published: (2023-08-01)

Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells
by: Seiichi Okabe, et al.
Published: (2023-09-01)

P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY
by: Timothy Hughes, et al.
Published: (2023-08-01)

A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib
by: Sarah Tomassetti, et al.
Published: (2022-11-01)

PB1980: ASC4KIDS: A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
by: Nobuko Hijiya, et al.
Published: (2023-08-01)

S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE
by: D. Rea, et al.
Published: (2022-06-01)

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
by: Thomas Ernst, et al.
Published: (2023-08-01)

Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
by: Takaaki Ono
Published: (2021-10-01)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
by: Zhenshu Xu, et al.
Published: (2009-03-01)

PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
by: T. Hughes, et al.
Published: (2022-06-01)

P681: MATCHING-ADJUSTED INDIRECT COMPARISON OF ASCIMINIB VERSUS OTHER TYROSINE KINASE INHIBITORS IN THIRD-OR-LATER LINE CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA
by: Ehab Atallah, et al.
Published: (2023-08-01)

P661: EFFECT OF VITAMIN K2 ON COVID-19 S1 PROTEIN-INDUCED CYTOTOXICITY AGAINST HUVECS AND ON THE ACTION OF ASCIMINIB IN ABELSON-TYROSINE-KINASE-INHIBITOR-RESISTANT CHRONIC MYELOGENOUS LEUKEMIA CELLS
by: Seiichi Okabe, et al.
Published: (2023-08-01)

PB1903: TRIAL IN PROGRESS: A MULTICENTER, OPEN-LABEL, PHASE IB/II STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
by: N. Hijiya, et al.
Published: (2022-06-01)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
by: Kota Yoshifuji, et al.
Published: (2022-10-01)

P704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL
by: T. Hughes, et al.
Published: (2022-06-01)

P688: ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
by: Ehab Atallah, et al.
Published: (2023-08-01)

P686: REAL-WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENT POPULATION
by: Massimo Breccia, et al.
Published: (2023-08-01)

S152: COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL
by: Nikola Čuřík, et al.
Published: (2023-08-01)

Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase.
by: Boultwood, J, et al.
Published: (2000)

Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors
by: Michael G. Martin, et al.
Published: (2011-12-01)

Nilotinib cause moyamoya disease in the treatment of chronic myelogenous leukemia during chronic phase: A case report
by: Jin-ping Liang, et al.
Published: (2023-09-01)

P673: ASCIMINIB MANAGMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION.
by: Elena Kuzmina, et al.
Published: (2023-08-01)

The case of successful therapy with Nilotinib in patients with Ph-positive chronic myelogenous leukemia of chronic phase resistant to Interferon and Gleevec
by: N. A. Afanasyeva, et al.
Published: (2022-11-01)

Preleukemic phase of chronic myelogenous leukemia: A diagnostic dilemma highlighting the significance of integrated reporting
by: Neelum Mansoor, et al.
Published: (2023-03-01)

P708: CANADIAN AND RUSSIAN EXPERIENCES OF ASCIMINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WHO FAILED MULTIPLE LINES OF TYROSINE KINASE INHIBITOR (TKI) THERAPY.
by: F. Khadadah, et al.
Published: (2022-06-01)

Occurrence of chronic lymphocytic leukemia in patients with chronic myelogenous leukemia
by: Pritish K Bhattacharyya
Published: (2013-01-01)

Analysis of telomere length in chronic myelogenous leukemia.
by: Boultwood, J, et al.
Published: (1997)

Analysis or telomere length in chronic myelogenous leukemia
by: Fidler, C, et al.
Published: (1998)

A mathematical model of chronic myelogenous leukemia
by: Neiman, B
Published: (2000)

Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia
by: Gopalarethinam Janani, et al.
Published: (2023-09-01)

Green crystals of death in chronic myelogenous leukemia
by: Mohammad Esmaeil Khedmati, et al.
Published: (2022-01-01)

Safety and Efficacy of Asciminib in Chronic Myeloid Leukemia Patient with Chronic Kidney Diseases: A Case Report
by: Awni Alshurafa, et al.
Published: (2024-01-01)

Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells.
by: Ondřej Mitrovský, et al.
Published: (2023-01-01)

P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA
by: Aram Bidikian, et al.
Published: (2023-08-01)

Chronic myelogenous leukemia: molecular monitoring in clinical practice
by: N. R. Ryabchikova, et al.
Published: (2014-07-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Chronic myelogenous leukemia: molecular monitoring in clinical practice
by: N. R. Ryabchikova, et al.
Published: (2014-07-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
by: Massimo Breccia, et al.
Published: (2023-08-01)

Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
by: Jee Hyun Kong, et al.
Published: (2020-05-01)